Drugs / CARBACYCLIC PHOSPHATIDIC ACID
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04229394 | Feb 2018 → Mar 2021 | osteoarthritis, knee | Orient Europharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05807529 | Nov 2022 → Dec 2024 | osteoarthritis, knee | Orient Europharma Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CARBACYCLIC PHOSPHATIDIC ACID | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594407 ↗ |
| Known as | 2ccPA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05807529 ↗ |
| Action | Inhibit | “2ccPA is a first-in-class phospholipase autotaxin (ATX) inhibitor” NCT05807529 ↗ |
| Modality | Small molecule | — CHEMBL4594407 ↗ |